The role of interleukin 17 in the pathogenesis of giant cell arteritis: new possibilities for pharmacotherapy
Giant cell arteritis (GCA) characterized by the paradoxical discrepancy between the high effectiveness of glucocorticoid (GCs) in the short term and the increase in signs associated with the persistence of inflammatory activity and the accumulation of organ damage induced by GCs in the long term, wh...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
IMA PRESS LLC
2024-12-01
|
| Series: | Научно-практическая ревматология |
| Subjects: | |
| Online Access: | https://rsp.mediar-press.net/rsp/article/view/3653 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849240259408166912 |
|---|---|
| author | E. L. Nasonov T. V. Beketova A. M. Satybaldyev |
| author_facet | E. L. Nasonov T. V. Beketova A. M. Satybaldyev |
| author_sort | E. L. Nasonov |
| collection | DOAJ |
| description | Giant cell arteritis (GCA) characterized by the paradoxical discrepancy between the high effectiveness of glucocorticoid (GCs) in the short term and the increase in signs associated with the persistence of inflammatory activity and the accumulation of organ damage induced by GCs in the long term, which indicates the need for the use of therapy, primarily in the direction of optimizing the use of GCs. New opportunities for pharmacotherapy of GCA are associated with the use of monoclonal antibodies (mAbs) that block the activity of cytokines involved in the immunopathogenesis of IMIRDs. Among pharmacological “targets”, interleukin (IL) 6, as well as IL-17, attracts special attention. Currently, several mAbs specific for IL-17 have been developed. The article summarizes data regarding the pathogenetic significance of IL-17 in GCA and the prospects for pharmacotherapy of GCA using mAbs to IL-17. |
| format | Article |
| id | doaj-art-dc72de37cf654b4ab382a336e02cc115 |
| institution | Kabale University |
| issn | 1995-4484 1995-4492 |
| language | Russian |
| publishDate | 2024-12-01 |
| publisher | IMA PRESS LLC |
| record_format | Article |
| series | Научно-практическая ревматология |
| spelling | doaj-art-dc72de37cf654b4ab382a336e02cc1152025-08-20T04:00:40ZrusIMA PRESS LLCНаучно-практическая ревматология1995-44841995-44922024-12-0162658258910.47360/1995-4484-2024-582-5893029The role of interleukin 17 in the pathogenesis of giant cell arteritis: new possibilities for pharmacotherapyE. L. Nasonov0T. V. Beketova1A. M. Satybaldyev2V.A. Nasonova Research Institute of Rheumatology ; I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University)I.M. Sechenov First Moscow State Medical University of the Ministry of Health Care of Russian Federation (Sechenov University) ; Central State Medical Academy of the Administrative Directorate of the President of the Russian Federation ; Moscow Polytechnic UniversityV.A. Nasonova Research Institute of RheumatologyGiant cell arteritis (GCA) characterized by the paradoxical discrepancy between the high effectiveness of glucocorticoid (GCs) in the short term and the increase in signs associated with the persistence of inflammatory activity and the accumulation of organ damage induced by GCs in the long term, which indicates the need for the use of therapy, primarily in the direction of optimizing the use of GCs. New opportunities for pharmacotherapy of GCA are associated with the use of monoclonal antibodies (mAbs) that block the activity of cytokines involved in the immunopathogenesis of IMIRDs. Among pharmacological “targets”, interleukin (IL) 6, as well as IL-17, attracts special attention. Currently, several mAbs specific for IL-17 have been developed. The article summarizes data regarding the pathogenetic significance of IL-17 in GCA and the prospects for pharmacotherapy of GCA using mAbs to IL-17.https://rsp.mediar-press.net/rsp/article/view/3653giant cell arteritisinterleukin 17secukinumab |
| spellingShingle | E. L. Nasonov T. V. Beketova A. M. Satybaldyev The role of interleukin 17 in the pathogenesis of giant cell arteritis: new possibilities for pharmacotherapy Научно-практическая ревматология giant cell arteritis interleukin 17 secukinumab |
| title | The role of interleukin 17 in the pathogenesis of giant cell arteritis: new possibilities for pharmacotherapy |
| title_full | The role of interleukin 17 in the pathogenesis of giant cell arteritis: new possibilities for pharmacotherapy |
| title_fullStr | The role of interleukin 17 in the pathogenesis of giant cell arteritis: new possibilities for pharmacotherapy |
| title_full_unstemmed | The role of interleukin 17 in the pathogenesis of giant cell arteritis: new possibilities for pharmacotherapy |
| title_short | The role of interleukin 17 in the pathogenesis of giant cell arteritis: new possibilities for pharmacotherapy |
| title_sort | role of interleukin 17 in the pathogenesis of giant cell arteritis new possibilities for pharmacotherapy |
| topic | giant cell arteritis interleukin 17 secukinumab |
| url | https://rsp.mediar-press.net/rsp/article/view/3653 |
| work_keys_str_mv | AT elnasonov theroleofinterleukin17inthepathogenesisofgiantcellarteritisnewpossibilitiesforpharmacotherapy AT tvbeketova theroleofinterleukin17inthepathogenesisofgiantcellarteritisnewpossibilitiesforpharmacotherapy AT amsatybaldyev theroleofinterleukin17inthepathogenesisofgiantcellarteritisnewpossibilitiesforpharmacotherapy AT elnasonov roleofinterleukin17inthepathogenesisofgiantcellarteritisnewpossibilitiesforpharmacotherapy AT tvbeketova roleofinterleukin17inthepathogenesisofgiantcellarteritisnewpossibilitiesforpharmacotherapy AT amsatybaldyev roleofinterleukin17inthepathogenesisofgiantcellarteritisnewpossibilitiesforpharmacotherapy |